Sign up for our newsletter to get the latest on the transformative forces shaping the global economy, delivered every Thursday.
VT-1953 treatment significantly reduced malignant fungating wound-associated malodor (primary endpoint) (P<0.001). Patients also reported significant improvements in lesion pain (P<0.001) and Quality ...